Carcinoma, Basal Cell Clinical Trial
Official title:
VISmodegib for ORbital and Periocular Basal Cell Carcinoma (VISORB)
Basal cell carcinoma (BCCA) is the most common human cancer, and frequently affects facial structures. While rarely fatal, facial BCCA can be disfiguring and expensive to treat. Vismodegib is a small molecule inhibitor of SMO developed for the treatment of tumors in which the Hh signaling pathway appears to contribute to the development and maintenance of tumorigenesis. Vismodegib was recently approved by the Food and Drug Administration (FDA) for treatment of metastatic and locally advanced BCCA. Recent reports have suggested that vismodegib treatment for orbital BCCA may facilitate eye preservation even if surgery is eventually required In order to assess the potential of vismodegib to improve the ophthalmic outcomes following treatment for orbital and/or periocular BCCA, this study will follow patients with globe-threatening orbital and lacrimal-threatening periocular BCCA who are being treated with vismodegib as standard of care. Patients with tumors that do not respond to treatment with Vismodegib, and those who have a good response but poor tolerance of Vismodegib, will be offered surgical excision of the tumor. Patients with a good response and good tolerance of Vismodegib may continue the treatment as long as clinically indicated.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00875381 -
Analysis of Melanocytes (Pigment Cells) in Sun-Exposed Skin
|
N/A | |
| Recruiting |
NCT04362722 -
Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients
|
Phase 2 | |
| Completed |
NCT00218829 -
DMSO-PDT of BCC - A 6 Year Follow up
|
N/A | |
| Completed |
NCT02674009 -
Observational Study to Determine the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Locally Advanced Basal Cell Carcinoma (laBCC)
|
||
| Recruiting |
NCT05970497 -
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Terminated |
NCT02956889 -
To Assess The Efficacy And Safety Of Vismodegib And Radiotherapy In Advanced Basal Cell Carcinoma
|
Phase 2 | |
| Completed |
NCT01204073 -
A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies
|
Phase 1 | |
| Completed |
NCT02029352 -
Topical Green Tea Ointment in Treatment of Superficial Skin Cancer
|
Phase 2/Phase 3 | |
| Completed |
NCT03569345 -
Basal Cell Carcinomas Treated With Ablative Fractional Laser and Ingenol Mebutate
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05463757 -
Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study
|
||
| Completed |
NCT00189280 -
Aldara for the Treatment of Large and/or Multiple sBCC
|
Phase 3 | |
| Completed |
NCT03541252 -
Topical Laser-assisted Combination Chemotherapy for Basal Cell Carcinoma- a Clinical Study
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05133427 -
HIFU for Treatment of Non-nodular and Recurrent BCC
|
N/A | |
| Active, not recruiting |
NCT02367547 -
Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitizers: HAL and BF-200 ALA Versus MAL
|
Phase 1/Phase 2 | |
| Completed |
NCT00007631 -
Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT05138328 -
Laser Treatment of Basal Cell Carcinoma Under Imaging Guidance
|
N/A | |
| Completed |
NCT03132636 -
PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
|
Phase 2 | |
| Completed |
NCT00847912 -
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
|
Phase 4 | |
| Enrolling by invitation |
NCT02666833 -
Optical Imaging for Preoperative Delineation of Nonmelanoma Skin Cancers
|
N/A | |
| Completed |
NCT01482104 -
New Versus Approved Methyl-aminolevulinate Photodynamic Therapy (MAL-PDT) Regime in Basal Cell Carcinoma (BCC)
|
N/A |